retatrutide cardiovascular may become one of the most important longevity-related drugs of this decade. Eli Lilly has just announced that its next-generation obesity drug achieved up to 28.3% average weight loss in a Retatrutide (LY-3437943) Market Analysis, 2033:
Description
10.1046/j.1445-2197.2003.02748.x 43 SoM
Based on the results, the researchers suggested that patients prescribed GLP-1s continue the medication prior to a procedure but also follow the standard fasting period and go on a liquid diet the day before, until more research is available
Common digestive side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating
The litigation is still in pretrial proceedings, with bellwether trials expected in late 2026 at the earliest
Mounjaro (tirzepatide) is an approved medication used for managing Type 2 diabetes, and more recently, for weight loss
